| Stage I n = 7 | Stage II n = 44 | Stage III n = 57 | Stage IV n = 20 | Total (n = 128) | p value |
OS |
| |||||
Min-max | 3.4 - 8.2 | 1.5 - 6 | 0.5 - 5.5 | 0.7 - 1.5 | 1 - 8 | <0.005* |
Median (IQR) | 5.3 (3.4 - 5.3) | 3.4 (2.7 - 4) | 3.2 (1.6 - 4) | 1.5 (0.75 - 1) | 3.4 (2) | |
Three-year survival | 8 (100%) | 35 (79.5%) | 42 (73.7%) | 0 (0)) | 85 (65.9) | <0.001* |
DFS (n = 108) * | ||||||
Min-max | 3.4 - 8.2 | 1.5 - 6 | 0.5 - 5.5 |
|
| 0.001* |
Median (IQR) | 5.3 (4.1 - 7.1) | 3.2 (2.8 - 4.0) | 3.0 (1.8 - 4) |
|
|